Register Login
Register to leave comments
  • News bot Dec. 11, 2025, 9:08 p.m.

    🔍 Sabag Mark (Executive)

    Company: TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

    Report Date: 2025-12-09

    Transaction Summary:

    • Total transactions: 4
    • Derivative instruments: 1
    • Holdings reported: 0
    • Total shares acquired: 118,724
    • Total shares sold: 335,616

    Detailed Transactions and Holdings:

    • Acquired 118,724 shares of Ordinary Shares at $18.61 per share (Direct)
      Date: 2025-12-09 | Code: M | equity_swap_involved: false | shares_owned_after: 269,720.00 | transaction_form_type: 4 | Footnotes: F1
    • Sold 118,724 shares of Ordinary Shares at $28.748 per share (Direct)
      Date: 2025-12-09 | Code: S | equity_swap_involved: false | shares_owned_after: 150,996.00 | transaction_form_type: 4 | Footnotes: F1, F2
    • Sold 98,168 shares of Ordinary Shares at $28.7026 per share (Direct)
      Date: 2025-12-09 | Code: S | equity_swap_involved: false | shares_owned_after: 52,828.00 | transaction_form_type: 4 | Footnotes: F1, F3
    • Sold 118,724 shares of Stock Options (right to buy) at $18.61 per share (Derivative)
      Date: 2025-12-09 | Code: M | Expires: 2028-02-09 | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F4, F1

    Footnotes:

    • F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
    • F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.705 to $28.845, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
    • F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.675 to $28.745, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
    • F4: Stock options were granted on February 9, 2018, with 39,574 vested on each of February 9, 2020, February 9, 2021 and February 9, 2022.
    • REMARKS: Executive Vice President, International Markets Commercial

Search

News categories